12.10.13
A study published in the Journal of the American College of Nutrition has shed light on how lignan supplementation may support menopausal women suffering from hot flashes.
In the report, “Pharmacokinetics and Bioavailability of Plant Lignan 7-Hydroxymatairesinol and Effects on Serum Enterolactone and Clinical Symptoms in Postmenopausal Women: A Single-Blinded, Parallel, Dose-Comparison Study,” postmenopausal females ages 50-75, who were not receiving hormone replacement therapy (HRT), were enrolled in either a 36 mg/d (low-dose) or 72 mg/d dose (high-dose) regimen for eight weeks. Following a single dose of 36 mg of HMRlignan, maximum plasma levels of 7-HMR were reached in one hour. Maximum plasma levels of Enterolactone were reached in 24 hours, suggesting that the ingredient can be taken once daily. In the 72 mg/day group, there was a 55 % reduction in hot flashes at week four and 80% fewer severe hot flashes at week eight, with no adverse events noted, and no estrogenic effects measured through blood tests.
A follow-up 12-week study with a larger cohort of postmenopausal women is currently underway to study the effects of HMRlignan on hot flashes.
For more information: http://linnea.ch; http://hmrlignan.com
In the report, “Pharmacokinetics and Bioavailability of Plant Lignan 7-Hydroxymatairesinol and Effects on Serum Enterolactone and Clinical Symptoms in Postmenopausal Women: A Single-Blinded, Parallel, Dose-Comparison Study,” postmenopausal females ages 50-75, who were not receiving hormone replacement therapy (HRT), were enrolled in either a 36 mg/d (low-dose) or 72 mg/d dose (high-dose) regimen for eight weeks. Following a single dose of 36 mg of HMRlignan, maximum plasma levels of 7-HMR were reached in one hour. Maximum plasma levels of Enterolactone were reached in 24 hours, suggesting that the ingredient can be taken once daily. In the 72 mg/day group, there was a 55 % reduction in hot flashes at week four and 80% fewer severe hot flashes at week eight, with no adverse events noted, and no estrogenic effects measured through blood tests.
A follow-up 12-week study with a larger cohort of postmenopausal women is currently underway to study the effects of HMRlignan on hot flashes.
For more information: http://linnea.ch; http://hmrlignan.com
